sapogenol | 147666-64-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: sapogenol
• 英文别名: oxytrogenin；(2S,4R,4aR,6aR,6aS,6bR,8aR,9S,10S,12aR,14bS)-4,10-dihydroxy-9-(hydroxymethyl)-2,4a,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-2-carboxylic acid
• CAS: 147666-64-6
• 化学式: C₃₀H₄₈O₅
• 分子量: 488.708
• InChiKey: URCNWIMQWSXMDE-UAPMTHOXSA-N

物化性质

• 沸点：
  620.6±55.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  35
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  sapogenol 在 吡啶 、 三乙基硼氢化锂 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 oxytrogenol acetate
  参考文献：
  名称：

  Studies on the constituents of leguminous plants. Part XXXIII. Three New Oleanene Glycosides from Sophora flavescens.

  摘要：

  从槐树（Sophora flavescens AITON）的新鲜根（豆科植物）中分离出三种新的齐墩果烷苷，槐黄苷 II-IV（2-4），以及槐黄苷 I（1）的相应甲基酯形式。根据化学反应和光谱分析，它们的结构被确定为氧杂蔷薇苷 3-O-α-L-鼠李糖吡喃糖基-(1→2)-β-D-半乳糖吡喃糖基-(1→2)-β-D-葡萄糖醛酸吡喃糖苷（2）、3-O-α-L-鼠李糖吡喃糖基-(1→2)-β-D-半乳糖吡喃糖基-(1→2)-β-D-葡萄糖醛酸吡喃糖苷氧杂蔷薇苷 22-O-α-L-阿拉伯糖吡喃糖苷（3）和 3-O-α-L-鼠李糖吡喃糖基-(1→2)-β-D-半乳糖吡喃糖基-(1→2)-β-D-葡萄糖醛酸吡喃糖苷氧杂蔷薇苷 22-O-β

  DOI：

  10.1248/cpb.40.2990
• 作为产物：
  描述：

  sophoraflavoside IV methyl ester 在 盐酸 、 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 2.5h， 生成 sapogenol
  参考文献：
  名称：

  Studies on the constituents of leguminous plants. Part XXXIII. Three New Oleanene Glycosides from Sophora flavescens.

  摘要：

  从槐树（Sophora flavescens AITON）的新鲜根（豆科植物）中分离出三种新的齐墩果烷苷，槐黄苷 II-IV（2-4），以及槐黄苷 I（1）的相应甲基酯形式。根据化学反应和光谱分析，它们的结构被确定为氧杂蔷薇苷 3-O-α-L-鼠李糖吡喃糖基-(1→2)-β-D-半乳糖吡喃糖基-(1→2)-β-D-葡萄糖醛酸吡喃糖苷（2）、3-O-α-L-鼠李糖吡喃糖基-(1→2)-β-D-半乳糖吡喃糖基-(1→2)-β-D-葡萄糖醛酸吡喃糖苷氧杂蔷薇苷 22-O-α-L-阿拉伯糖吡喃糖苷（3）和 3-O-α-L-鼠李糖吡喃糖基-(1→2)-β-D-半乳糖吡喃糖基-(1→2)-β-D-葡萄糖醛酸吡喃糖苷氧杂蔷薇苷 22-O-β

  DOI：

  10.1248/cpb.40.2990

文献信息

• Studies on the constituents of leguminous plants. Part XXXVI. Triterpene Glycosides from the Bark of Robinia pseudo-acacia L. I.
  作者：Baoliang CUI、Junei KINJO、Toshihiro NOHARA

  DOI：10.1248/cpb.40.2995

  日期：——

  From the bark of Robinia pseudo-acacia L., five new triterpene glycosides, robiniosides A-D (3, 5-7) and compound III (4), were isolated and their structures were elucidated as 3-O-α-L-rhammopyranosyl(1→2)-β-D-glucopyranosyl(1→2)-β-D-glucuronopyranosyl 3β, 22β-dihydroxyolean-12-en-29-oic acid (3), 3-O-α-L-rhamnopyranosyl(1→2)-β-D-galactopyranosyl(1→2)-β-D-glucuronopyranosyl 3β, 22β, 24-trihydroxyolean-12-en-29-oic acid (4), whose sapogenol was unambiguously characterized and designated as oxytrogenin, 3-O-α-L-rhamnopyranosyl(1→2)-β-D-gluco-pyranosyl(1→2)-β-D-glucuronopyranosyl oxytrogenin (5), 3-O-α-L-rhamnopyranosyl(1→2)-β-D-galactopyranosyl(1→2)-β-D-glucuronopyranosyl oxytrogenin 22-O-α-L-rhamnopyranoside (6), 3-O-α-L-rhamnopyranosyl(1→2)-β-D-gluco-pyranosyl(1→2)-β-D-glucuronopyranosyl oxytrogenin 22-O-α-L-rhamnopyranoside (7), respectively, together with two known triterpene glycosides, kaikasaponin III (1) and 3-O-α-L-rhamnopyranosyl(1→2)-β-D-galactopyranosyl(1→2)-β-D-glucuronopyranosyl 3β, 22β-dihydroxyolean-12-en-29-oic acid (2).

  yranosyl(1→2)-β-D-galactopyranosyl(1
• Polynucleotide binding complexes comprising sterols and saponin
  申请人：Nordic Vaccine Technology A/S

  公开号：EP2011517A1

  公开（公告）日：2009-01-07

  The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.

  本发明涉及由甾醇和皂甙组成的复合物。这些复合物能够结合包括多核苷酸在内的遗传决定因子。复合物可进一步包含亲脂分子，可选择包含接触基团和/或靶向配体的亲脂分子和/或糖分子。复合物可进一步包括免疫原决定簇和/或抗原决定簇和/或药物和/或诊断化合物。在更进一步的实施方案中，复合物可被包括生物可降解微球在内的封装剂封装。本发明还涉及通过治疗和/或手术对个体进行治疗的药物组合物和方法、美容治疗方法以及对人体或动物体进行诊断的方法。
• POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS
  申请人：Nordic Vaccine Technology A/S

  公开号：EP1377320B1

  公开（公告）日：2008-10-01